cyanocob(III)alamin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
cyanocob(III)alamin — no detected effect on fasting blood glucose
Evidence strength: moderate.FindingNull result“In the vitamin B12 group, the levels of FBG significantly decreased; however, the between-group comparison revealed a nonsignificant P-value (P = 0.167).”
Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 1000 µg cyanocobalamin, one oral tablet daily for 12 weeks
- Population
- Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.2022PMID:3598216210.1038/s41598-022-18195-8Industry fundedPermalink
To cite this finding: https://catalystproject.ai/e/01M5MERK16ZXF6PCAEFA6K56FK